Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD

Add to watchlist

4.7200+0.0400 (+0.85%)

As of 2:31PM EDT. Market open.

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	4.6800
Open	4.6800
Bid	4.7700 x N/A
Ask	4.7900 x N/A
Day's Range	4.6000 - 4.9100
52 Week Range	0.4000 - 5.9900
Volume	2,086,040
Avg. Volume	1,601,018

Market Cap	1.071B
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.1280
Earnings Date	May 14, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

CNW Group
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
GlobeNewswire
“The Science Behind Using Psychedelics To Treat Mental Health Disorders And Addiction Is Compelling”
Jim Cramer discussed psychedelics on his June 15, 2021 program and said big drug companies tried, and failed, to treat major depression. Here are four psychedelic companies you need to know about that are addressing the mental health crisis.OTCStockReview.com News Commentary ATLANTA, June 16, 2021 (GLOBE NEWSWIRE) -- Jim Cramer discussed psychedelics on his June 15, 2021 program and said, “The science behind using psychedelics to treat mental health disorders and addiction is compelling." He als
- Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
  Reuters
- Verve Therapeutics upsized IPO prices above the expected range
  MarketWatch
PR Newswire
MindMed Announces Chief Executive Officer Transition
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comp